Search Results - "Harb, Diala"
-
1
S12 Impact of Pancrelipase on Stool Frequency and Consistency in Patients With Exocrine Pancreatic Insufficiency Due to Chronic Pancreatitis or Pancreatic Surgery: Analysis of Randomized Trial Patient-Reported Daily Symptoms
Published in The American journal of gastroenterology (01-10-2022)Get full text
Journal Article -
2
-
3
-
4
Assessment of Weight Loss and Gastrointestinal Symptoms Suggestive of Exocrine Pancreatic Dysfunction After Acute Pancreatitis
Published in Clinical and translational gastroenterology (15-12-2020)“…Studies evaluating the natural history of exocrine pancreatic dysfunction (EPD) after acute pancreatitis (AP) are sparse. This study aims to assess incidence…”
Get full text
Journal Article -
5
EP 80317, a ligand of the CD36 scavenger receptor, protects apolipoprotein E-deficient mice from developing atherosclerotic lesions
Published in The FASEB journal (01-11-2005)“…ABSTRACTCD36, a type B scavenger receptor expressed on macrophages, appears to play a major role in fatty streak formation through scavenging oxidatively…”
Get full text
Journal Article -
6
Effects of pancreatic enzyme replacement therapy (PERT) on overall survival (OS) in patients (pts) with advanced pancreatic ductal adenocarcinoma (APDAC) and evidence of pancreatic enzyme insufficiency (PEI): A single institution, retrospective, cohort study
Published in Journal of clinical oncology (01-06-2023)“…e16254 Background: Weight loss (WL)/cachexia is common in APDAC and associated with multiple adverse pt outcomes. Current NCCN guidelines recommend PERT in…”
Get full text
Journal Article -
7
Effect of pancreatic enzyme replacement therapy (PERT) on body weight in advanced pancreatic cancer (APC)
Published in Journal of clinical oncology (01-02-2023)“…698 Background: Malnutrition/cachexia is common in PC and is associated with multiple adverse patient (pt) outcomes. Current NCCN guidelines recommend PERT in…”
Get full text
Journal Article -
8
Real-World Patient Experience With Pancreatic Enzyme Replacement Therapy in the Treatment of Exocrine Pancreatic Insufficiency
Published in Pancreas (01-01-2024)“…This study aimed to provide patients insights on the management of exocrine pancreatic insufficiency (EPI) with pancreatic enzyme replacement therapy (PERT). A…”
Get more information
Journal Article -
9
Combination of Ibrutinib with CD19 Chimeric Antigen Receptor (CAR) T Cells Suggests Greater Contribution to CAR T-Cell Efficacy Than Other Approved BTK Inhibitors in the Preclinical Setting
Published in Blood (02-11-2023)“…Background:CD19-directed CAR T-cell therapy has demonstrated remarkable clinical benefits for patients with B-cell malignancies, but impaired CAR T-cell…”
Get full text
Journal Article -
10
Impact of pancreatic enzyme replacement therapy (PERT) on clinical outcomes in nonresected pancreatic cancer (PC): Initial results
Published in Journal of clinical oncology (20-01-2021)“…Abstract only 400 Background: Current NCCN guidelines recommend PERT use in PC patients (pts) with symptoms of EPI. However, little evidence exists regarding…”
Get full text
Journal Article -
11
Introduction and practical approach to exocrine pancreatic insufficiency for the practicing clinician
Published in International journal of clinical practice (Esher) (01-02-2018)“…In exocrine pancreatic insufficiency (EPI), the quantity and/or activity of pancreatic digestive enzymes are below the levels required for normal digestion,…”
Get more information
Journal Article -
12
-
13
Economic Impact of Pancreatic Enzyme Replacement Therapy (PERT) in Pancreatic Cancer Patients Who May Have Exocrine Pancreatic Insufficiency (EPI) Following Pancreatic Surgery: Presidential Poster Award: 98
Published in The American journal of gastroenterology (01-10-2018)Get full text
Journal Article -
14
Economic Impact of Pancreatic Enzyme Replacement Therapy (PERT) in Pancreatic Cancer Patients Who May Have Exocrine Pancreatic Insufficiency (EPI) Following Pancreatic Surgery
Published in The American journal of gastroenterology (01-10-2018)“…Introduction: Exocrine pancreatic insufficiency (EPI) is a known consequence of pancreatic head resection. Following surgery, patients with EPI should be…”
Get full text
Journal Article -
15
Targeting CD36 With EP 80317 Reduces Remote Inflammatory Response to Hind Limb Ischemia‐Reperfusion in Mice
Published in Journal of biochemical and molecular toxicology (01-12-2024)“…Reperfusion of ischemic skeletal muscle triggers oxidative stress and an immediate inflammatory reaction, leading to damage of distant organs such as the…”
Get full text
Journal Article -
16
Factors Influencing Prostate‐Specific Antigen Response among Men Treated with Testosterone Therapy for 6 Months
Published in Journal of sexual medicine (01-11-2014)“…Factors influencing prostate‐specific antigen (PSA) changes in men undergoing testosterone (T) therapy have not been well studied. The aim of this study was to…”
Get full text
Journal Article -
17
The role of the scavenger receptor CD36 in regulating mononuclear phagocyte trafficking to atherosclerotic lesions and vascular inflammation
Published in Cardiovascular research (01-07-2009)“…Aims CD36 has been shown to associate with non-receptor Src kinases to activate mitogen-activated protein kinases and trigger cytoskeletal remodelling,…”
Get full text
Journal Article -
18
A Growth Hormone-Releasing Peptide that Binds Scavenger Receptor CD36 and Ghrelin Receptor Up-Regulates Sterol Transporters and Cholesterol Efflux in Macrophages through a Peroxisome Proliferator-Activated Receptor γ-Dependent Pathway
Published in Molecular endocrinology (Baltimore, Md.) (01-12-2006)“…Macrophages play a central role in the pathogenesis of atherosclerosis by accumulating cholesterol through increased uptake of oxidized low-density…”
Get full text
Journal Article -
19
EP80317, a selective ligand of the CD36 scavenger receptor, reduces 111In‐labeled macrophages trafficking to atherosclerotic lesions in apoE‐deficient mice
Published in The FASEB journal (01-03-2006)“…Our recent studies have shown that long‐term (12 weeks) treatment with growth hormone‐releasing peptides (GHRPs), as ligands of the CD36 scavenger receptor,…”
Get full text
Journal Article